Department of Biological Sciences, The University of Alabama in Huntsville, Huntsville, AL 35899, United States.
Department of Medicine, Division of Infectious Diseases, University of Tennessee Health Science Center, Memphis, TN 38163, United States.
Vaccine. 2021 Mar 19;39(12):1773-1779. doi: 10.1016/j.vaccine.2021.01.075. Epub 2021 Feb 26.
The M protein of group A streptococci (Strep A) is a major virulence determinant and protective antigen. The N-terminal sequence of the protein defines the more than 200 M types of Strep A and also contains epitopes that elicit opsonic antibodies, some of which cross-react with heterologous M types. Current efforts to develop broadly protective M protein-based vaccines are directed at identifying potential cross-protective epitopes located in the N-terminal regions of cluster-related M proteins for use as vaccine antigens. In this study, we have used a comprehensive approach using the recurrent neural network ABCpred and IEDB epitope conservancy analysis tools to predict 16 residue linear B-cell epitopes from 117 clinically relevant M types of Strep A (~88% of global Strep A infections). To examine the immunogenicity of these epitope-based vaccines, nine peptides that together shared ≥60% sequence identity with 37 heterologous M proteins were incorporated into two recombinant hybrid protein vaccines, in which the epitopes were repeated 2 or 3 times, respectively. The combined immune responses of immunized rabbits showed that the vaccines elicited significant levels of antibodies against all nine vaccine epitopes present in homologous N-terminal 1-50 amino acid synthetic M peptides, as well as cross-reactive antibodies against 16 of 37 heterologous M peptides predicted to contain similar epitopes. The epitope-specificity of the cross-reactive antibodies was confirmed by ELISA inhibition assays and functional opsonic activity was assayed in HL-60-based bactericidal assays. The results provide important information for the future design of broadly protective M protein-based Strep A vaccines.
A 组链球菌(Strep A)的 M 蛋白是主要的毒力决定因素和保护性抗原。该蛋白的 N 端序列定义了超过 200 种 Strep A M 型,并且还包含引发调理抗体的表位,其中一些与异源 M 型发生交叉反应。目前,开发广泛保护性 M 蛋白疫苗的努力旨在鉴定位于相关 M 蛋白簇的 N 端区域的潜在交叉保护性表位,用作疫苗抗原。在这项研究中,我们使用了一种综合方法,使用反复神经网络 ABCpred 和 IEDB 表位保守性分析工具,从 117 种临床相关的 Strep A M 型(约占全球 Strep A 感染的 88%)中预测了 16 个残基线性 B 细胞表位。为了研究这些基于表位的疫苗的免疫原性,将 9 个与 37 种异源 M 蛋白共享≥60%序列同一性的肽段分别整合到两种重组混合蛋白疫苗中,其中表位分别重复 2 或 3 次。免疫兔子的综合免疫反应表明,疫苗在同源 N 端 1-50 个氨基酸合成 M 肽中引发了针对所有 9 个疫苗表位的显著水平的抗体,以及针对预测含有类似表位的 37 种异源 M 肽中的 16 种的交叉反应性抗体。交叉反应性抗体的表位特异性通过 ELISA 抑制试验得到证实,并在基于 HL-60 的杀菌测定中测定了功能调理活性。这些结果为未来设计广泛保护性 M 蛋白基于 Strep A 疫苗提供了重要信息。